Axsome Therapeutics, Inc. (AXSM) Business Profile

What it does

Axsome Therapeutics is a biopharmaceutical company that develops and sells medicines for central nervous system conditions. Its medicines are intended for patients with psychiatric and neurological disorders, and its development programs seek treatments for additional conditions.

Its commercial portfolio includes AUVELITY for major depressive disorder in adults and agitation associated with Alzheimer’s disease; SUNOSI for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy; and SYMBRAVO for the acute treatment of migraine in adults, with or without aura. Axsome launched AUVELITY for Alzheimer’s disease agitation in 2026.

The company also develops medicines that have not yet received approval for their proposed uses. These include AXS-05, the combination used in AUVELITY, for smoking cessation; solriamfetol, the active ingredient in SUNOSI, for conditions including attention deficit hyperactivity disorder and binge eating disorder; and AXS-12 for cataplexy in narcolepsy. Cataplexy involves a sudden reduction or loss of muscle tone while a person is awake.

Axsome’s other programs include AXS-14 for fibromyalgia, AXS-17 for epilepsy and AXS-20 for schizophrenia. The company was incorporated in 2012, has its corporate and executive offices in New York, and is led by chief executive officer Herriot Tabuteau.

How it makes money

Axsome earns revenue primarily by selling its approved medicines. It also receives royalties and milestone payments related to SUNOSI in territories where another company has commercialization rights. For the year ended December 31, 2025, total revenue was $638.5 million; in the third quarter of 2026, total revenue was $259.7 million.

Product sales were $633.8 million in FY2025, representing 99.3% of revenue. Sales are recorded net of estimates for items such as government and health-plan rebates, distribution fees, returns and patient co-pay assistance. Prescription demand can recur as patients continue treatment, although the company expects revenue from its marketed products to fluctuate with demand from quarter to quarter.

In the third quarter of 2026, AUVELITY generated $207.6 million in net product sales. SUNOSI generated $38.5 million in net product sales, alongside $1.2 million in royalty revenue and $8.5 million in milestone revenue. SYMBRAVO generated $3.9 million in net product sales during the quarter.

The company licenses SUNOSI to Pharmanovia for Europe and certain countries in the Middle East and North Africa. Under that agreement, Axsome receives a royalty percentage in the mid-twenties on net sales in the licensed territory and is eligible for sales-based and other milestone payments.

Revenue from an investigational medicine depends on its successful development, regulatory approval and commercialization. Axsome may also enter licensing or collaboration agreements, although those arrangements may not generate future revenue.

Customers and how it sells

Axsome’s medicines are prescribed by healthcare professionals for patients with depression, sleep-related conditions and migraine. The company promotes its products through its own sales organization in the United States and works with wholesalers and distributors as part of its commercialization infrastructure. Government and private payers also influence access through coverage and reimbursement.

In Q3 2026, Axsome reported that primary care represented nearly 40% of AUVELITY prescribers and 25% of total prescriptions. It added approximately 8,200 new AUVELITY prescribers in the quarter, bringing the number of unique prescribers since launch to approximately 77,000. The company reported payer coverage for approximately 89% of lives across channels for AUVELITY and approximately 57% for SYMBRAVO.

Three customers each accounted for a share of FY2025 revenue. Their names are not specified in the available customer figures.

The United States is Axsome’s direct commercial focus. SUNOSI is also approved in Europe, where Pharmanovia holds exclusive marketing rights, as well as in certain countries in the Middle East and North Africa. SK Biopharmaceuticals retains SUNOSI rights in 12 Asian markets, including China, Korea and Japan. Axsome intends to use partners selectively for commercialization outside the United States.

Suppliers and costs

Axsome uses clinical and commercial supply agreements and third parties to help manage clinical trials. Its commercial agreements are generally non-exclusive, with obligations generally arising when it orders supplies or requests services. The company also plans to expand external manufacturing capacity as needed for additional products.

Cost of revenue includes drug formulation, manufacturing and packaging, as well as shipping, inventory management and royalties. Research and development spending includes clinical and preclinical studies, manufacturing, employees and outside contractors. Selling, general and administrative expenses include personnel, marketing, commercial activities, facilities, professional fees and patent costs.

Axsome pays royalties connected to its licensed and acquired programs. AUVELITY sales carry a 3.0% royalty on net sales under licenses from Antecip, an entity owned by chief executive and board chairman Herriot Tabuteau. The company treats those payments as a related-party transaction. SUNOSI carries royalty commitments to Jazz, SK and Aerial; the company also has milestone obligations associated with SUNOSI and other acquired programs.

In the third quarter of 2026, cost of revenue was $17.8 million and selling, general and administrative expenses were $203.1 million. The increase in the latter from the prior-year quarter was primarily driven by commercialization activities for AUVELITY and SYMBRAVO.

Competitive position

Axsome competes across several treatment categories. For Alzheimer’s disease agitation, Otsuka and Lundbeck market Rexulti, and other companies are developing therapies. For smoking cessation, approved products include Pfizer’s Chantix, GSK’s Zyban and nicotine replacement therapies.

In narcolepsy, approved medicines for symptoms include Jazz’s Xyrem and Xywav, Teva’s Provigil and Nuvigil, and Harmony Biosciences’ Wakix. Axsome is developing AXS-12 for cataplexy in narcolepsy, while companies including Takeda, Centessa and Harmony are developing treatments for narcolepsy symptoms. In fibromyalgia, approved products include Pfizer’s Lyrica, AbbVie’s Savella and Tonix’s Tonmya.

Axsome uses proprietary formulation and medicinal chemistry technologies in its medicines. AUVELITY uses metabolic inhibition technology, while SYMBRAVO uses MoSEIC technology, designed to improve absorption. Axsome also has licensed intellectual property and data for programs including AXS-05, AXS-12 and AXS-14. AXS-12 has orphan drug designation, which may provide a period of marketing exclusivity if it is approved.

Our reading: The company’s formulations, licenses and potential regulatory exclusivity provide some protection, but their strength varies by product and indication. Our reading: Existing approved alternatives and competing development programs limit the protection those assets provide against therapeutic competition.

Growth opportunities

Axsome is pursuing growth through its marketed medicines, additional uses for existing compounds and new drug candidates. AUVELITY’s expansion into Alzheimer’s disease agitation added an indication beyond adult depression. The company estimates that AUVELITY is positioned to generate at least $8 billion in annual revenue at peak; that is a company estimate, not current sales.

For AXS-05, Axsome initiated the SUMMIT Phase 3 smoking cessation trial in August 2026 and anticipates top-line results in the second half of 2027. It is also studying solriamfetol in ADHD, binge eating disorder, shift work disorder and depression with excessive daytime sleepiness. Targeted enrollment has been reached in the ENGAGE Phase 3 binge eating disorder trial, with results expected in the first quarter of 2027.

The FDA is reviewing Axsome’s application for AXS-12 for cataplexy in narcolepsy, with a target action date of May 1, 2027. Axsome estimates that narcolepsy affects approximately 185,000 individuals in the United States. For AXS-14 in fibromyalgia, the company anticipates completing enrollment in the FORWARD Phase 3 trial in the third quarter of 2027.

Axsome also anticipates starting a pivotal Phase 3 trial of AXS-20 in schizophrenia and clinical trials of AXS-17 in epilepsy in the first half of 2027. Each program requires further development or regulatory approval before sales for its proposed use.

Structural risks

• Losses and funding: Axsome has incurred operating and net losses and expects continuing operating losses. It believes its cash will fund anticipated operations into cash flow positivity under its current plan, but says its assumptions could prove wrong and additional financing may not be available on acceptable terms.
• Clinical and regulatory outcomes: The company depends substantially on its products and cannot guarantee that candidates will complete trials, receive approval or be commercialized. The FDA refused to file the AXS-14 fibromyalgia application because it found the submission insufficiently complete for substantive review; Axsome initiated the FORWARD study to address the feedback.
• Access and demand: Successful commercialization depends on demand from patients and clinicians, reimbursement, acceptable safety profiles and competition. Axsome says the Alzheimer’s agitation market still requires significant education.
• Concentrated customers: Three unnamed customers each accounted for a share of FY2025 revenue. Axsome’s commercialization also depends on maintaining agreements with wholesalers and distributors.
• Third parties and rights: Axsome relies on external manufacturing, clinical service providers and licensing agreements. It says a breach of its SUNOSI-related agreements would materially harm its business and prospects.

Bottom line

Our reading

Our reading: Axsome combines a commercial medicines business with a substantial development pipeline, so its future depends on both prescription demand and the outcome of clinical and regulatory programs. Its existing products and licensed technology provide a commercial base, while customer concentration, ongoing losses, reimbursement and competition remain important exposures. Pipeline approvals could expand the business, but they are not assured.